- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00234104
A Dose-finding Study of OPC-41061 in Treatment of Cardiac Edema (Congestive Heart Failure)
November 6, 2013 updated by: Otsuka Pharmaceutical Co., Ltd.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Dose Response of OPC-41061 in Congestive Heart Failure Patients With Extracellular Volume Expansion
This drug is being developed to treat cardiac edema.
The primary purpose of this study is to investigate the dose response for body weight in seven-day repeated oral administration of OPC-41061 at 15, 30, and 45 mg or placebo in patients with extracellular volume expansion secondary to CHF despite taking furosemide at 40 mg/d or more.
This study is being conducted in Japan.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
122
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Tokyo, Japan
- Otsuka Pharmaceutical Co., Ltd.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients with CHF who exhibit edema, jugular venous distention, hepatomegaly, pulmonary congestion, or 3rd sound due to extracellular volume expansion
- Hospitalized patients or patients who can be hospitalized for the study from the commencement of the observation period to the end-of-study examination
- Men and women between the ages of 20 and 80 (non-inclusive) at the time of giving consent
- Patients who have taken furosemide at 40 mg/d or more (oral dosing) without alteration of dosage for the 3 days of the observation period
- Patients whose body weight has been stable (±1.0 kg) for 2 days prior to commencement of study drug administration
Exclusion Criteria:
- Patients with unstable heart failure (acute heart failure, acute exacerbation of chronic heart failure, etc)
- Patients with an implanted ventricular assist device
Patients who have undergone or are scheduled to undergo any of the following procedures
- Heart surgery involving thoracotomy within 60 days prior to the screening examination
- Pacemaker implant surgery involving bilateral pacing within 60 days prior to the screening examination
- Angioplasty, electrophysiologic device implantation, ventricular assist device implantation, heart transplant, or other cardiac surgery scheduled within 30 days after the screening examination
Patients with any of the following diseases, complications, or symptoms
- Suspected hypovolemia
- Onset of acute myocardial infarction within 30 days prior to the screening examination
- Hypertrophic cardiomyopathy (excluding diastolic phase)
- Definitively diagnosed active myocarditis or amyloid cardiomyopathy
- Valvular heart disease with significant stenosis
- Untreated thyroid disease
- Progressive neurological disease (Alzheimer's disease, Parkinson's disease, multiple sclerosis, etc) or severe episodic neurological disease (epilepsy, Guillain-Barre syndrome, etc)
- Diabetes with poor glycemic control
- Anuria
- Hepatic coma
- Hyponatremia of moderate or greater severity (serum Na < 120 mEq/L)
Patients with a history of the following conditions
- Occurrence of sustained ventricular tachycardia or ventricular fibrillation within 30 days prior to the screening examination (except for patients using an implantable cardioverter-defibrillator)
- Evident cerebral infarction
- Multiple stroke
- Occurrence of a cerebrovascular accident within 30 days prior to the screening examination
- Hypersensitivity or idiosyncratic reaction to benzazepine derivatives, such as benazapril
- Patients with a history of drug abuse or alcoholism in the past year
- Patients in a state of morbid obesity with a body mass index (weight[kg] ÷ height [m]2) over 35
- Patients with a supine systolic arterial blood pressure of less than 90 mmHg
- Patients with any of the following abnormal laboratory values: Hemoglobin <9 g/dL, total bilirubin >3.0 mg/dL, serum creatine >3.0 mg/dL, serum Na >147 mEq/L, or serum K >5.5 mEq/L
- Patients not capable of taking oral medication
- Patients who are nursing, pregnant, capable of pregnancy, or intending to become pregnant during or shortly after the study period
- Patients who have taken a study drug other than OPC-41061 within 30 days prior to screening
- Patients who have previously taken OPC-41061 in this study or another study of OPC-41061
- Patients otherwise judged by the principal investigator or attending investigator to be inappropriate for inclusion in the study (eg, patients with hepatic cirrhosis, renal disease, etc.)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Body Weight
Time Frame: Baseline, at the time of final trial drug administration
|
The body weight change from baseline following final trial drug administration
|
Baseline, at the time of final trial drug administration
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2004
Primary Completion (Actual)
January 1, 2006
Study Completion (Actual)
January 1, 2006
Study Registration Dates
First Submitted
October 4, 2005
First Submitted That Met QC Criteria
October 4, 2005
First Posted (Estimate)
October 6, 2005
Study Record Updates
Last Update Posted (Estimate)
December 25, 2013
Last Update Submitted That Met QC Criteria
November 6, 2013
Last Verified
November 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 156-03-001
- JapicCTI-050038
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Edema
-
Eye-yon MedicalCompletedCORNEAL EDEMAIsrael, Poland
-
Federico II UniversityCompletedPseudophakic Cystoid Macular Edema
-
California Retina ConsultantsRegeneron PharmaceuticalsCompletedDiabetic Macular Edema | Cystoid Macular EdemaUnited States
-
Postgraduate Institute of Medical Education and...CompletedDiabetic Macular Edema | Vision Disorders | Macular Edema, Cystoid | Clinically Significant Macular EdemaIndia
-
National Cardiovascular Center Harapan Kita Hospital...CompletedMyocardial Edema
-
OcugenNot yet recruitingDiabetic Macular Edema | Center Involved Diabetic Macular Edema
-
Eye-yon MedicalCompletedChronic Cornel EdemaNetherlands, Israel, Germany, Spain
-
University of RochesterNeuroMetrix, Inc.Active, not recruiting
-
Luca MarinEnrolling by invitation
Clinical Trials on OPC-41061(Tolvaptan)
-
Otsuka Pharmaceutical Co., Ltd.Completed
-
Otsuka Pharmaceutical Development & Commercialization...TerminatedHyponatremia | Inappropriate ADH Syndrome | Dilutional HyponatremiaUnited States
-
Otsuka Pharmaceutical Development & Commercialization...CompletedAutosomal Dominant Polycystic Kidney DiseaseUnited States
-
Otsuka Pharmaceutical Development & Commercialization...RecruitingAutosomal Recessive Polycystic Kidney Disease (ARPKD)United States, Belgium, Spain, Germany, United Kingdom, Poland
-
Otsuka Pharmaceutical Co., Ltd.Completed
-
Otsuka Pharmaceutical Development & Commercialization...CompletedChronic Kidney Disease | Autosomal Dominant Polycystic Kidney DiseaseAustralia, Belgium, Italy, Spain, Sweden, United States, Canada, Netherlands, Czechia, Poland, Germany, Russian Federation, Hungary, Israel, Puerto Rico, Argentina, Denmark, South Africa, United Kingdom, Norway, France, Romania
-
Otsuka Pharmaceutical Development & Commercialization...CompletedAutosomal Dominant Polycystic Kidney DiseaseUnited States
-
Otsuka Pharmaceutical Co., Ltd.Completed
-
Otsuka Pharmaceutical Co., Ltd.Completed
-
Otsuka Pharmaceutical Development & Commercialization...Otsuka Pharmaceutical Co., Ltd.CompletedPolycystic Kidney Disease, Autosomal DominantUnited States, Belgium, United Kingdom, Russian Federation, France, Australia, Netherlands, Italy, Japan, Denmark, Romania, Poland, Canada, Argentina, Germany